Purpose

The 2011 International Workshop on Meibomian Gland Dysfunction was organized to build consensus on various disease aspects of MGD. The purpose of this review was to examine the influence of the MGD Workshop on clinical trials by examining their attributes prior to and after the Workshop.

Methods

A search for clinical trials using the terms “Meibomian Gland Dysfunction” was conducted using the “Interventional Studies” filter on ClinicalTrials.gov, and selecting studies with posting and start dates prior to (2004–2010) and after the Workshop (2012–2018). The inclusion criteria, outcome measures, and study designs and rigor were examined.

Results

A total of 32 post-Workshop and 5 pre-Workshop clinical trials were identified with the search. The proportion of pre-Workshop trials using generic diagnosis and systematic assessments to define MGD was similar to that of post-Workshop trials. In both pre- and post-Workshop trials, symptoms, altered gland secretions, and alteration in tear film were the most frequent clinical attributes used to define MGD. The most frequent outcome measures used for pre-Workshop and post-Workshop trials were also similar: symptoms, meibum quality/expressibility, and tear stability.

Conclusions

The nature of the inclusion criteria, and the clinical attributes used to define MGD during the pre-Workshop period were similar to those of the post-Workshop period, suggesting that the MGD Workshop has had a minimal impact on the design of interventional trials for MGD.

中文翻译：

---

2011年国际睑板腺功能障碍研讨会对睑板腺功能障碍临床试验属性的影响。

目的

组织了2011年睑板腺功能障碍国际研讨会，以就MGD的各个疾病方面达成共识。这篇综述的目的是通过检查研讨会之前和之后的属性来检查MGD研讨会对临床试验的影响。

方法

使用ClinicalTrials.gov上的“介入研究”过滤器对使用“睑板腺功能障碍”一词进行的临床试验进行搜索，并选择在（2004-2010）之前和在研讨会之前（2012-2018）开始和发布日期的研究）。纳入标准，结果测量，研究设计和严谨性得到了检查。

结果

搜索共鉴定了32个车间后临床试验和5个车间前临床试验。使用通用诊断和系统评估定义MGD的车间前试验的比例与车间后试验的比例相似。在车间进行前后的试验中，症状，腺体分泌物的改变和泪膜的改变是定义MGD的最常见临床特征。在车间前和车间后试验中使用的最频繁的结局指标也相似：症状，胫骨质量/可表达性和泪液稳定性。

结论

纳入标准的性质以及在车间前阶段用于定义MGD的临床属性与车间后阶段的相似，这表明MGD研讨会对MGD介入试验的设计影响最小。